Big Pharma At Crossroads After GSK Payment Reforms

Law360, New York (December 19, 2013, 5:44 PM ET) -- Faced with a flood of False Claims Act and bribery allegations, drugmakers will be forced to take a hard look at their compensation practices after GlaxoSmithKline PLC this week took the revolutionary steps of sharply limiting payments to doctors and no longer basing employee wages on hitting sales targets, experts say.

GSK's actions, taken amid yet another major inquiry into the business dealings of the British pharmaceutical giant, strike at the heart of how prescription medicines are promoted and sold — and how drugmakers get into...
To view the full article, register now.